Tag: bioequivalence standards
FDA Bioequivalence Standards for NTI Drugs: Special Requirements Explained
The FDA enforces stricter bioequivalence standards for narrow therapeutic index (NTI) drugs like warfarin, digoxin, and phenytoin, requiring tighter limits (90-111%) and replicate studies to ensure patient safety. These rules prevent dangerous fluctuations in blood levels that can occur with generics.
Crossover Trial Design: How Bioequivalence Studies Are Structured
Crossover trial designs are the gold standard for bioequivalence studies, using each participant as their own control to reduce variability and sample size. Learn how AB/BA and replicate designs work, when to use them, and what regulators require.